Is MOTS-c Legal in Washington State?

What Is MOTS-c and Why Does Its Legal Status Matter?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded entirely within mitochondrial DNA. Its discovery was published in 2015 by Lee et al. In Cell Metabolism, and follow-up animal research suggested it could improve insulin sensitivity, reduce diet-induced obesity, and extend healthy lifespan in mice. Those findings generated significant commercial interest long before any human phase III data existed.

Because it is a peptide, not a small molecule, its regulatory path in the United States runs through FDA drug-approval rules, compounding pharmacy statutes, and state medical-practice acts rather than through DEA scheduling. The gap between early animal data and full FDA approval creates a space where clinicians, patients, and compounding pharmacies must make legal judgments with incomplete statutory guidance.

Why the Legal Question Is Genuinely Complicated

Several factors collide at once here. MOTS-c is not a naturally occurring human nutrient that could qualify as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA). It is a synthetic peptide with pharmacological effects, which places it squarely under the Federal Food, Drug, and Cosmetic Act (FD&C Act) definition of a "drug" once it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. [1]

At the same time, FDA has not approved any new drug application (NDA) or biologics license application (BLA) for MOTS-c. That combination, a substance that is technically a "drug" under federal law but lacks an approved application, is the root of the gray-zone problem.

The Research-Chemical Loophole

Vendors may sell MOTS-c labeled "for research use only, not for human consumption." This phrasing does not exempt the compound from FDA enforcement if regulators determine the actual intended use is human administration. FDA has sent warning letters to peptide suppliers using this label when the marketing context suggested human use. The label shifts legal risk onto the buyer and prescriber rather than eliminating it. [2]

Federal Regulatory Framework: FDA Approval, DSHEA, and the FD&C Act

Understanding Washington State's position requires understanding federal law first, because federal law is the ceiling that state rules cannot exceed.

FDA Drug Approval Status

As of January 2025, MOTS-c has no approved NDA, BLA, or abbreviated NDA (ANDA) with the FDA. A search of the FDA's Drugs@FDA database returns zero results for "MOTS-c." That absence means no manufacturer has completed the Phase I through Phase III clinical trial pathway required for FDA approval for any indication in humans. [3]

This does not make the peptide illegal to prescribe per se. Physicians in the United States retain broad authority to prescribe approved drugs for unapproved (off-label) uses and, under certain circumstances, to prescribe unapproved compounds prepared by licensed compounding pharmacies. The complexity arises precisely in that second scenario.

Dietary Supplement Status: Not Applicable

MOTS-c does not qualify as a dietary supplement. DSHEA defines dietary supplements as vitamins, minerals, amino acids, herbs, or other botanicals. A synthetic mitochondrial-derived peptide does not fit within those categories. Sellers who market MOTS-c as a supplement are misclassifying it, and FDA has legal authority to act against such marketing. [4]

Controlled Substance Status

MOTS-c is not scheduled under the Controlled Substances Act (CSA). The DEA's five schedules cover substances with abuse potential, physical or psychological dependence risk, and related concerns. Current published data does not indicate MOTS-c carries those properties. No DEA rule proposes scheduling it. This means possession without a prescription is not a criminal offense under federal drug-scheduling law, though it may still violate FD&C Act provisions regarding unapproved drugs intended for human use. [5]

Compounding Pharmacy Rules: 503A, 503B, and the Bulk Substances Lists

Compounding is the legal mechanism by which many peptides reach patients in the United States. Two sections of the FD&C Act govern compounding: Section 503A covers traditional, patient-specific compounding pharmacies, and Section 503B covers outsourcing facilities that can produce larger batches. Both sections restrict which bulk drug substances (active pharmaceutical ingredients not yet in an FDA-approved product) a pharmacy may use.

The 503A Bulk Substances List

For a 503A pharmacy to compound using a bulk drug substance, that substance must appear on the FDA's "Category 1" list (substances nominated for and evaluated as appropriate for compounding) or must not be on the "negative list" (substances FDA has evaluated and found not appropriate). FDA evaluates substances based on clinical need, safety data, and other factors.

MOTS-c does not appear on the published Category 1 positive list as of January 2025. It also does not appear on the negative list. It sits in a nomination limbo: nominated or discussed in industry channels but not yet formally evaluated and approved by FDA for 503A use. A 503A pharmacy that compounds MOTS-c for human administration is therefore operating without explicit federal authorization, creating meaningful legal risk for that pharmacy. [6]

The 503B Outsourcing Facility List

Section 503B outsourcing facilities face even stricter rules. They may only use bulk drug substances that FDA has placed on a specific 503B-approved list. MOTS-c does not appear on that list. A 503B facility producing MOTS-c for human use would be out of compliance with 503B requirements. [7]

What This Means in Practice

A compounding pharmacy that prepares MOTS-c for human administration is taking on regulatory risk, not the patient directly. FDA enforcement priorities have historically focused on pharmacies producing adulterated, mislabeled, or unsafe products. Many compounding pharmacies continue to prepare peptides not on the positive lists because FDA has not issued a formal "negative list" determination for every peptide. That is a business and legal risk calculation, not a patient-side criminal exposure.

Patients receiving a compounded MOTS-c prescription from a licensed pharmacy under a valid physician order are not themselves violating a criminal statute.

Washington State Law: Pharmacy Board, Medical Practice Act, and Prescribing Authority

Washington State does not have a statute that specifically names MOTS-c or bans it by name. The applicable state-level rules are the Uniform Controlled Substances Act (RCW 69.50), the pharmacy practice act (RCW 18.64), and the medical practice act (RCW 18.71).

Washington State Pharmacy Board

The Washington State Department of Health, Pharmacy Quality Assurance Commission (PQAC), oversees compounding pharmacies operating in the state. PQAC rules align with, and in most cases defer to, federal USP standards and FDA compounding guidelines. The Commission has not issued a specific advisory or rule naming MOTS-c. A Washington-licensed compounding pharmacy faces the same federal 503A framework uncertainty described above, plus a duty to comply with USP <797> sterile compounding standards if MOTS-c is prepared as an injectable (the most common clinical route). [8]

Physician Prescribing Authority in Washington

A Washington-licensed physician (MD or DO), nurse practitioner (ARNP), or physician assistant (PA-C) with prescribing authority can legally write a prescription for MOTS-c as an unapproved compound for an individual patient. The state medical practice act does not create a list of approved-only compounds. Prescribers retain professional discretion to order compounded preparations when a clinical rationale exists, provided the prescribing is not deceptive or grossly negligent.

The prescriber bears professional responsibility for documenting clinical rationale, obtaining informed consent (including disclosure of the unapproved status of the compound), and monitoring for adverse effects.

No Washington State Criminal Prohibition

Possession of MOTS-c without a prescription is not a criminal offense under Washington's Uniform Controlled Substances Act because the peptide is not scheduled. However, obtaining it without a valid prescription from sources that present it as a human drug may still implicate federal FD&C Act provisions. Practically, state law enforcement is not targeting individual MOTS-c possessors. The risk is regulatory, not criminal, for most patients.

Anti-Doping Status: WADA and USADA Rules

Competitive athletes subject to anti-doping codes face an additional layer of restriction that is entirely separate from legality in the criminal or civil sense.

WADA S0 Prohibition

The World Anti-Doping Agency (WADA) Prohibited List includes a category called S0: "Non-Approved Substances." S0 covers any pharmacological substance not approved by any regulatory authority for human therapeutic use, meaning any substance without a current valid marketing authorization as a medicinal product in any country. MOTS-c has no such authorization anywhere in the world as of January 2025. It therefore falls under S0 and is prohibited in-competition and out-of-competition for all athletes subject to WADA rules. [9]

A positive test for MOTS-c could result in a two-year or four-year suspension under WADA's World Anti-Doping Code 2021. Athletes should understand this is not a criminal prohibition but a sports-governance consequence that can end a career.

USADA Guidance

The United States Anti-Doping Agency (USADA) applies WADA rules to U.S. Olympic, Paralympic, and affiliated athletes. USADA's online "Supplement 411" resource does not list MOTS-c specifically because it is not a supplement, but the S0 category applies regardless of whether a substance is listed by name. [10]

Clinical Evidence Base: What the Research Actually Shows

The legal gray zone exists partly because the clinical evidence is at an early stage. Here is an honest accounting of where the science stands as of early 2025.

Animal and In-Vitro Data

The foundational 2015 Cell Metabolism paper by Lee et al. (PMID 25738459) demonstrated that MOTS-c administered to mice on a high-fat diet reduced weight gain, improved insulin sensitivity, and activated AMPK in skeletal muscle. A 2019 follow-up by the same group showed that circulating MOTS-c levels decline with age in both mice and humans, and that exogenous MOTS-c extended healthy lifespan in aged mice. These are compelling mechanistic findings, but animal pharmacokinetics and doses do not translate directly to human clinical practice. [11]

Human Observational Data

A 2019 study published in Aging (PMID 31586380) examined serum MOTS-c levels across age groups in 70 humans and found a statistically significant inverse correlation between circulating MOTS-c and insulin resistance (HOMA-IR), with P<0.001. This is associational data, not interventional. It cannot establish that administering exogenous MOTS-c to humans with insulin resistance is safe or effective. [12]

No Completed Phase III RCT in Humans

As of January 2025, ClinicalTrials.gov lists no completed Phase III randomized controlled trial of MOTS-c in any human population. There are early-phase exploratory protocols. The absence of Phase III data is the central reason FDA has not approved this compound and why the clinical rationale for prescribing it to individual patients requires careful physician judgment and transparent patient consent.

Dose and Route: What Compounding Protocols Use

Clinicians in the peptide-therapy space have reported using subcutaneous injection protocols ranging from 5 mg to 10 mg per dose, administered two to five times per week, drawing on dose-extrapolation from mouse studies and early human tolerability reports. These doses are not validated by clinical trials and should be understood as empirical. A physician prescribing MOTS-c should document this rationale explicitly in the medical record.

How to Access MOTS-c Lawfully in Washington State

Given the framework above, a Washington resident who wants to pursue MOTS-c therapy has a specific set of steps that represent the most legally defensible path.

Step 1: Consult a Licensed Washington Prescriber

A board-certified physician, ARNP, or PA-C licensed in Washington State can evaluate whether a clinical rationale exists, order relevant labs (fasting insulin, HOMA-IR, HbA1c, metabolic panel), and write a prescription if appropriate. Telehealth visits with Washington-licensed prescribers are permitted under state law, including for follow-up management.

Step 2: Use a Licensed Compounding Pharmacy

The prescription must go to a pharmacy licensed in Washington State or to an out-of-state 503A compounding pharmacy that is lawfully allowed to ship into Washington. The pharmacy should follow USP <797> sterile compounding standards for injectable preparations. Patients should ask the pharmacy whether it is PCAB-accredited (Pharmacy Compounding Accreditation Board), as PCAB accreditation indicates voluntary compliance with quality benchmarks above the minimum legal requirement.

Step 3: Avoid Unregulated Online Sources

Purchasing MOTS-c from online vendors who sell it without requiring a prescription and who label it "for research use only" creates personal legal ambiguity and, more practically, carries unknown purity and sterility risks. A 2018 FDA laboratory analysis of compounded peptides (including BPC-157 and other research peptides sold online) found that several samples contained particulate matter, microbial contamination, or incorrect concentrations. [13] Applying that finding as a reasonable proxy, unverified online MOTS-c carries measurable quality risk.

Step 4: Document Informed Consent

Any prescriber following best practices will document that the patient understands MOTS-c is not FDA-approved, that human clinical trial data is limited, that the compounding pharmacy is preparing it under conditions of regulatory uncertainty, and that the patient accepts these risks voluntarily. This documentation protects both the patient and the prescriber.

Regulatory Outlook: Could Washington or the FDA Clarify This?

FDA has been actively revisiting its peptide compounding policy. In 2023 and 2024, the agency sent warning letters to multiple compounding pharmacies preparing peptides including BPC-157, TB-500 (thymosin beta-4), and others, citing the absence of bulk-substance authorization. MOTS-c has not been the named subject of a public FDA warning letter as of January 2025, but the enforcement trajectory suggests that peptides lacking 503A positive-list status face increasing regulatory scrutiny.

A formal nomination to FDA's 503A bulk substances review process could change MOTS-c's status. If FDA placed MOTS-c on the Category 1 positive list, compounding pharmacies could prepare it with full federal authorization. If FDA placed it on the negative list, compounding would be explicitly prohibited. Until one of those determinations is made, the gray zone persists.

Washington State, independently, could issue a PQAC advisory restricting compounding of specific unapproved peptides, but the Commission has not signaled any such move specific to MOTS-c.